产品
编 号：F741278
分子式：C22H26O4
分子量：354.44
分子式：C22H26O4
分子量：354.44
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 1800188-47-9
产品详情
生物活性：
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.
体内研究：
Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100?mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice.Animal Model:HFD-induced obese male C57BL/6J mice
Dosage:10, 30, and 100?mg/kg
Administration:Orally administered for 6 weeks
Result:Led to significant dose-dependent body weight reduction by 4.0?g (8.3%), 10?g (21%), and 19?g (40%), respectively, compared to the 48.1?g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100?mg/kg.
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.
体内研究：
Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100?mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice.Animal Model:HFD-induced obese male C57BL/6J mice
Dosage:10, 30, and 100?mg/kg
Administration:Orally administered for 6 weeks
Result:Led to significant dose-dependent body weight reduction by 4.0?g (8.3%), 10?g (21%), and 19?g (40%), respectively, compared to the 48.1?g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100?mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备